Physician profile
Alan Tesson
NPI 1518000637
$5,506.12
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $321 · 2021: $494 · 2022: $1,894 · 2023: $1,979 · 2024: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.69 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,303.20 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,258.95 | 2021-2024 | Caplyta |
| Abbvie INC. | $805.13 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $734.88 | 2019-2024 | Invega Sustenna |
| Alkermes, INC. | $565.03 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $322.97 | 2019-2023 | Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $259.21 | 2019-2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.89 | 2019 | |
| Indivior INC. | $59.29 | 2022-2023 | Perseris |
| Lundbeck LLC | $36.76 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.64 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Tesson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.